Press Release by Industry
- All Industries
- Agriculture
- Automotive
- Banking
- Business Technology
- Construction
- Consumer Goods
- Consumer Technology
- Education
- Energy
- Entertainment & Media
- Environment
- Financial Services
- Food and Beverage
- General Business
- Healthcare
- Hospitality
- Information Technology
- Insurance
- Heavy Industry & Manufacturing
- Media
- Mining
- People & Culture
- Pharmaceuticals
- Policy & Public Interest
- Real Estate
- Retail
- Sports
- Telecommunications
- Transportation
- Travel
- Utilities
Healthcare - Press Releases
Published on Fri 21 Mar 2025 12:00:55 UTC
Strategic Acquisition of Intellectual Property of BRII-179, a Wholly Owned Phase 2b Asset Capable of Combining with Multiple HBV Treatment Modalities for Cure
Published on Fri 21 Mar 2025 12:00:52 UTC
SHANGHAI, CAMBRIDGE, Mass. and ROTTERDAM, Netherlands, March 21, 2025 /PRNewswire/ -- HarbourBioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in immunology and oncology, today announced a global strategic collaboration with AstraZeneca to discoverand developnext-generation multi-specific antibodies for immunology, oncology and beyond. The strategic collaboration includes an option to license multiple programs utilizing Harbour BioMed's proprietary Harbour Mice fully human antibody technology platform in multiple therapeutic areas and a$105 million equity investment by AstraZeneca in Harbour BioMed.
Published on Fri 21 Mar 2025 12:00:49 UTC
PRINCETON, N.J., March 21, 2025 /PRNewswire/ --Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need,announced today its recent accomplishments and financial results for the year ended December 31, 2024.
Published on Fri 21 Mar 2025 12:00:44 UTC
Gundry MD Total Restore is a unique dietary supplement that contains L-Glutamine as one of its key ingredients. It is specifically designed to address common gut health issues such as occasional gas, bloating, digestive problems, cravings for unhealthy foods, and unwanted weight gain, and aims to support overall health and well-being.
Published on Fri 21 Mar 2025 11:48:29 UTC
AMSTERDAM, March 21, 2025 /PRNewswire/ -- From March 11 to 14,Aquatech Amsterdam 2025, a premier global event in water treatment, took place at the RAI Amsterdam Convention Centre. Recognized as an industry-leading exhibition covering all aspects of water treatment, this year's event drew over 900 exhibitors, 25,000 professional visitors, and extensive international media coverage.
Published on Fri 21 Mar 2025 11:45:57 UTC
Final chance to join Europe's top pre-accelerator for EU entrepreneurs, featuring special prizes for innovators from key emerging regions
Published on Fri 21 Mar 2025 11:45:54 UTC
A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including new semaglutide cardiovascular data and the surprising parallels between parakeet and human brain activity.
Published on Fri 21 Mar 2025 7:21:10 UTC
HOUSTON, March 20, 2025 /PRNewswire/ -- PCCA, a leading FDA-registered supplier of active pharmaceutical ingredients, excipients and consulting for the compounding industry, today announced Gus Bassani, PharmD,will become chief executive officer of its U.S. business unit on April 1, elevating a company veteran with extensive scientific leadership.
Published on Fri 21 Mar 2025 7:21:06 UTC
Journal of Emergency Nursing also honors emergency nursing legend
Published on Fri 21 Mar 2025 7:21:02 UTC
SAN CLEMENTE, Calif., March 20, 2025 /PRNewswire/ --Angelalign Technology Inc. ("Angelalign Technology" or the "Company") (6699.HK) released its financial results for fiscal year 2024. Driven by rapid expansion in global markets and continued innovation in digital orthodontics, the Company delivered a robust global performance despite complex global market challenges.
Published on Fri 21 Mar 2025 7:21:01 UTC
WASHINGTON, March 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2025 on Tuesday, April 22, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations.
Published on Fri 21 Mar 2025 7:20:57 UTC
Comprehensive Analysis Exposes Severe Lung Diseases from Artificial Stone Dust Exposure
Published on Fri 21 Mar 2025 7:20:54 UTC
HIGHLAND PARK, Ill., March 20, 2025 /PRNewswire/ -- The Collaborative Community Housing Initiativeis excited to announce its recent acquisition of a former memory care community in Highland Park, Illinois. This purchase marks a significant step forward in CCHI's mission to create an inclusive living environment for individuals with intellectual and developmental disabilities.
Published on Fri 21 Mar 2025 7:20:51 UTC
Un anlisis exhaustivo expone enfermedades pulmonares graves por la exposicin al polvo de piedra artificial
Published on Fri 21 Mar 2025 7:20:47 UTC
Grant provides Native Veterans access to the Mobilized Native Intensive Clinical Program
Published on Fri 21 Mar 2025 7:20:41 UTC
DARZALEX has significant market potential as a leading monoclonal antibody for multiple myeloma treatment. Its approval in various combinations for both newly diagnosed and relapsed/refractory patients has expanded its reach. The multiple myeloma market is expected to grow steadily, with DARZALEX contributing significantly due to its strong clinical efficacy and growing adoption.
Published on Fri 21 Mar 2025 7:20:36 UTC
VICTORIA, BC, March 20, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the fourth quarter of 2024. All dollar values are in U.S. dollars unless stated otherwise.
Published on Fri 21 Mar 2025 7:20:33 UTC
A case study on how a leading European dermatology company sought regulatory intelligence support to navigate the CDSCO framework. The company aimed to gain a comprehensive understanding of key guidelines, requirements, and approval processes to file their market-ready product in India successfully.
Published on Fri 21 Mar 2025 7:20:28 UTC
LOS ANGELES, March 20, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its fourth quarter and full-year ended December 31, 2024, and provided a corporate update.
Published on Fri 21 Mar 2025 7:20:24 UTC
SAN FRANCISCO, March 20, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference:
Published on Fri 21 Mar 2025 7:20:22 UTC
TREMFYA is the only IL-23i to demonstrate clinical remission and endoscopic response, both at one year, with a fully subcutaneous induction regimen
Published on Fri 21 Mar 2025 7:20:17 UTC
HealthMark Group celebrates another year as a USA Today Top Workplace honoree, which recognizes companies nationwide taking the lead in employee satisfaction
Published on Fri 21 Mar 2025 7:20:14 UTC
EAST HANOVER, N.J., March 20, 2025 /PRNewswire/ -- Novartis today announced that oral Fabhalta (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment ofadults with C3 glomerulopathy (C3G), to reduce proteinuria, making it the first and only treatment approved for this condition1-4.
Published on Fri 21 Mar 2025 7:20:13 UTC
ALPHARETTA, Ga., March 20, 2025 /PRNewswire/ -- OrthoMinds, LLC ("OrthoMinds") is providing notice of a recent data security event.OrthoMinds is notifying clients and potentially impacted individuals of the event. This notice provides information about the event, OrthoMinds' response, and steps potentially impacted individuals may take. OrthoMinds takes the confidentiality, privacy, and security of information very seriously.
Published on Fri 21 Mar 2025 7:19:49 UTC
LANSING, Mich., March 20, 2025 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG) will issue its third-quarter earnings release before the opening of the market on Wednesday, April 9, 2025. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time, to discuss the financial results.
Press Release by Industry
- All Industries
- Agriculture
- Automotive
- Banking
- Business Technology
- Construction
- Consumer Goods
- Consumer Technology
- Education
- Energy
- Entertainment & Media
- Environment
- Financial Services
- Food and Beverage
- General Business
- Healthcare
- Hospitality
- Information Technology
- Insurance
- Heavy Industry & Manufacturing
- Media
- Mining
- People & Culture
- Pharmaceuticals
- Policy & Public Interest
- Real Estate
- Retail
- Sports
- Telecommunications
- Transportation
- Travel
- Utilities